Merck & Co. Inc. (MRK)

86.62
0.10 0.12
NYSE : Health Technology
Prev Close 86.72
Open 86.22
Day Low/High 86.22 / 86.94
52 Wk Low/High 66.10 / 87.25
Volume 958.34K
Avg Volume 9.82M
Exchange NYSE
Shares Outstanding 2.56B
Market Cap 222.52B
EPS 2.30
P/E Ratio 41.00
Div & Yield 2.20 (2.49%)
FDA Grants Priority Review To Merck's Supplemental Biologics License Application For KEYTRUDA® (pembrolizumab) For The Treatment Of Merkel Cell Carcinoma, A Rare Form Of Skin Cancer

FDA Grants Priority Review To Merck's Supplemental Biologics License Application For KEYTRUDA® (pembrolizumab) For The Treatment Of Merkel Cell Carcinoma, A Rare Form Of Skin Cancer

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.

Broker Darlings Of The Dow: Merck Ranks As A Top 15 Analyst Pick

Broker Darlings Of The Dow: Merck Ranks As A Top 15 Analyst Pick

A study of analyst recommendations at the major brokerages shows that Merck & Co Inc is the #10 broker pick, on average, out of the 30 stocks making up the Dow Jones Industrial Average, according to ETF Channel. Merck & Co Inc also comes in above the median of analyst picks among the broader S&P 500 index components, claiming the #112 spot out of 500.

The New #14 Most Shorted Dow Component: Merck

The New #14 Most Shorted Dow Component: Merck

The most recent short interest data has been released for the 08/15/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Dow Jones Industrial Average by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Why Large-Cap Pharma Stocks Like Pfizer and Lilly Might Still Have Upside

Why Large-Cap Pharma Stocks Like Pfizer and Lilly Might Still Have Upside

A 'bullish perfect storm of technical factors' is powering the recent strength in large-cap pharma stocks, says Evercore ISI's Rich Ross.

Here's Why You Should Invest in Immunotherapy Companies

Here's Why You Should Invest in Immunotherapy Companies

Immunotherapy may be the future of fighting cancer and companies are racing to capitalize on that. We spoke with the CEO of the Damon Runyon Cancer Research Foundation to find out why.

Eisai And Merck Announce European Commission Grants Marketing Authorization For LENVIMA® (lenvatinib) As First-Line Treatment In Adults With Advanced Or Unresectable Hepatocellular Carcinoma

Eisai And Merck Announce European Commission Grants Marketing Authorization For LENVIMA® (lenvatinib) As First-Line Treatment In Adults With Advanced Or Unresectable Hepatocellular Carcinoma

Eisai and Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the European Commission (EC) has granted a marketing authorization for the oral receptor tyrosine kinase (RTK) inhibitor LENVIMA ® (lenvatinib), as a...

Drug Companies Start Keeping Prices in Check to Avoid Government Crackdown

Drug Companies Start Keeping Prices in Check to Avoid Government Crackdown

The industry has taken to smaller, voluntary measures to avoid serious federal action on pricing.

Jim Cramer: What Does Politics Have to Do With Johnson & Johnson's P/E?

Jim Cramer: What Does Politics Have to Do With Johnson & Johnson's P/E?

The answer is plenty, but you can't trade that.

Merck Could Suffer a Downward Correction to Unwind the Overbought Conditions

Merck Could Suffer a Downward Correction to Unwind the Overbought Conditions

Merck is vey overbought on a number of time frames.

Merck Shares Slip Despite 'Milestone' Lung Cancer Drug Approval

Merck Shares Slip Despite 'Milestone' Lung Cancer Drug Approval

Merck shares retreat as regulatory approval ramps up speculation.

Jim Cramer: This Is a Rotation, Not a Recession

Jim Cramer: This Is a Rotation, Not a Recession

There's too much evidence of economic strength, so don't interpret these moves as a sign of a real slowdown.

Family Offices Inject Capital Into Budding Cannabis Industry

Family Offices Inject Capital Into Budding Cannabis Industry

Family offices, which manage billions of dollars and have much fewer restrictions on how they deploy capital, have been wading into the cannabis space with increasing frequency.

Why One Money Manager Is Telling Clients to Raise Cash Right Now

Why One Money Manager Is Telling Clients to Raise Cash Right Now

Time to brace for a summer pullback?

Merck Becomes #17 Most Shorted Dow Stock, Replacing Travelers Companies

Merck Becomes #17 Most Shorted Dow Stock, Replacing Travelers Companies

The most recent short interest data has been released for the 07/31/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Dow Jones Industrial Average by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

4 of My Recent Income Picks Had Good Earnings

From Stag Industrial to Merck, the numbers looked good.

This Market Isn't Weak, It's Just Tired

The market needs a pullback.

Merck's Head Of Human Resources Mirian M. Graddick-Weir To Retire; Steven C. Mizell Will Assume Role On Oct. 1

Merck's Head Of Human Resources Mirian M. Graddick-Weir To Retire; Steven C. Mizell Will Assume Role On Oct. 1

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the retirement effective November 30, 2018 of its chief human resources officer Mirian M.

Selumetinib Granted Orphan Designation In Europe For Neurofibromatosis Type 1

Selumetinib Granted Orphan Designation In Europe For Neurofibromatosis Type 1

AstraZeneca and Merck (NYSE:MRK), known as MSD outside the U.S.

Healthcare Bulls Are Feeling Great After Earnings

Healthcare Bulls Are Feeling Great After Earnings

Investors may have been betting that the 'drug pricing war' was a non-event and that the upcoming earnings cycle would show continued growth and profitability in the healthcare sector.

European Medicines Agency Adopts Positive Opinion For KEYTRUDA® (pembrolizumab) Combination With Pemetrexed And Platinum Chemotherapy For The First-Line Treatment Of Metastatic Nonsquamous Non-Small Cell Lung Cancer

European Medicines Agency Adopts Positive Opinion For KEYTRUDA® (pembrolizumab) Combination With Pemetrexed And Platinum Chemotherapy For The First-Line Treatment Of Metastatic Nonsquamous Non-Small Cell Lung Cancer

Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of KEYTRUDA ®,...

Stocks Trim Losses at Close of Trading

Stocks Trim Losses at Close of Trading

Stocks ended the day off their lows but still in the red Friday as tech share weakness overcame strong GDP data.

Merck Beats Estimates and Raises Guidance, But Stock Plops 2%

Merck Beats Estimates and Raises Guidance, But Stock Plops 2%

Shares fell on Friday morning despite positive results for the second quarter.

Global Stocks Grind Higher as Trade Tension Ease: U.S. GDP in Focus

Global Stocks Grind Higher as Trade Tension Ease: U.S. GDP in Focus

With global trade tensions easing and U.S. corporate earnings continuing to impress, stocks are set to close out the week on solid footing, with gains possibly extended by a better-than-expected reading for U.S. economic growth over the second quarter.

Amazon, Facebook, GDP, Intel and Exxon - 5 Things You Must Know

Amazon, Facebook, GDP, Intel and Exxon - 5 Things You Must Know

U.S. stock futures rise modestly on Friday ahead of data on second-quarter GDP; Amazon's profit in the second quarter tops $2 billion; Intel shares fell despite the chipmaker beating earnings forecasts.

Financial Highlights Package

Financial Highlights Package

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the second quarter of 2018.

KEYTRUDA® (pembrolizumab) Is The First Anti-PD-1 Therapy Approved In China For Advanced Melanoma

KEYTRUDA® (pembrolizumab) Is The First Anti-PD-1 Therapy Approved In China For Advanced Melanoma

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that KEYTRUDA ®, Merck's anti-PD-1 therapy, has been approved by the China National Drug Administration (CNDA) for the treatment of adult patients with unresectable or...

TheStreet Quant Rating: A+ (Buy)